Authors reply: “Vasopressor use during renal replacement therapy”

ElsevierVolume 89, October 2025, 155156Journal of Critical CareAuthor links open overlay panel, , Section snippetsCRediT authorship contribution statement

Raghavan Murugan: Conceptualization, Writing – original draft, Writing – review & editing. Jorge Echeverri: Writing – original draft, Writing – review & editing. Javier A. Neyra: Conceptualization, Writing – review & editing.

Funding/support

Vantive Health LLC funded the original study. This publication was subject to review by internal employees from Baxter Healthcare Corporation before submission for protection of Confidential Information. However, the authors retain full responsibility for the content of this publication. The results presented in this article have not been published previously in whole or in part.

Declaration of competing interest

Murugan and Neyra are authors of the publication and have received consulting fees from Vantive Health LLC for data analysis. Echeverri is a full-time employee at Vantive Health LLC. Murugan received research grants from the United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Baxter, Inc., Vantive Health LLC, and consulting fees from Baxter Inc., AM Pharma Inc., Bioporto Inc. La Jolla Inc., Fresenius Medical Care, and Novartis Inc., unrelated to this

Acknowledgments

All authors critically reviewed and approved the final version for submission.

View full text

© 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Comments (0)

No login
gif